ClinicalTrials.gg
CompletedNCT00537485Updated Mar 19, 2014Results posted

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

A Phase 2/3 interventional study of SPM 962 and placebo in Early Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
16th of 42
180 · median 123
Started
2007
with 5 others
Phase 2/3
2 of 44
none open now
Registered
13th of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 16th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 2/3, and was the 13th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

03

Conditions studied

  • Early Parkinson's Disease

Browse trials for

Keywords

  • SPM 962
  • rotigotine
  • Parkinson's disease
  • monotherapy
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)"
  2. Subject is 30 years \< > 80 years at the time of
  3. Hoehn \& Yahr stage 1- 3
  4. Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test

Exclusion criteria

Exclusion Criteria:

  1. Subject has previously participated in a trial with SPM 962
  2. Subject is on L-dopa treatment for total of over 6 months at the time of
  3. Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline
  4. Subject has orthostatic hypotension
  5. Subject has a history of epilepsy, convulsion and other
  6. Subject has a complication of serious cardiac disorder/arrhythmia or has the history
  7. Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)
  8. Subject has serious abnormal at screening i.e.; 1) Subject has more than 450 msec of values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline
  9. Subject has congenital long QT syndrome
  10. Subject has serum potassium of less than 3.5 mEq/L at screening test.
  11. Subject has total of 3.0 mg/dL and above or (GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test
  12. Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test
  13. Subject has a history of allergy to topical medicine, e.g. transdermal patch
  14. Subject is pregnant, nursing, or is child bearing potential while the trial
  15. Subject is receiving therapy with prohibited drug specified in the study protocol
  16. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant
  17. Subject has dementia
  18. Subject is unable to give consent
  19. Subject is participating in another trial of an drug or done so within 12 weeks prior to the initial treatment
  20. Investigator judges that subject is inappropriate as a study subject with other reasons
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    1

    Drug: SPM 962

  • Placebo comparator
    2

    Drug: placebo

Interventions

  • transdermal application, 1 time per day

  • Drugplacebo

    transdermal application, 1 time per day

06

What researchers measure

Primary outcomes

  1. Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3

    Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, end of maintenance period

Secondary outcomes

  1. Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period

    Time frame: baseline, end of maintenance period

  2. Mean Change in UPDRS Part 2 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, every two weeks

  3. Efficacy Rate in UPDRS Part 2 Sum Score

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

    Time frame: Baseline, every two weeks

  4. UPDRS Part 3 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, every two weeks

  5. Efficacy Rate in UPDRS Part 3 Sum Score

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

    Time frame: Baseline, every two weeks

  6. UPDRS Part 1 Sum Score

    MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, every two weeks

  7. UPDRS Part 4 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, every two weeks

  8. Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4

    Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, every two weeks

  9. The Modified Hoehn and Yahr Stage

    Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.

    Time frame: Baseline, end of maintenance period

07

Results

Posted Mar 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM962Placebo
Started9090
Completed7580
Not completed1510
Withdrew: Adverse event105
Withdrew: Withdrawal by subject32
Withdrew: Withdrawal by subject13
Withdrew: Physician decision10

Outcome measures

PrimaryChange From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3

Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, end of maintenance period
Reported as:
Mean · Scores on a scale
Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3
Scores on a scaleSPM962Placebo
Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3-8.4 ± 9.7-4.1 ± 8.2
Statistical analysis
  • SPM962 vs Placebo · t-test, 2 sided · p = 0.002 · Mean difference (final values): -1.3 · 95% CI -3.7 to 1.1
SecondaryEfficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period

Time frame:
baseline, end of maintenance period
Reported as:
Number · Percentage of participants
Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3
Percentage of participantsSPM962Placebo
≥20% decrease71.6 (62.2 to 81.0)40.9 (30.6 to 51.3)
≥30% decrease55.7 (45.3 to 66.1)29.5 (20.0 to 39.1)
Statistical analysis
  • SPM962 vs Placebo · Chi-squared, Corrected · p = <0.001 · Risk difference (rd): 30.7 · 95% CI 16.7 to 44.6
  • SPM962 vs Placebo · Chi-squared, Corrected · p = <0.001 · Risk difference (rd): 26.1 · 95% CI 12.0 to 40.2
SecondaryMean Change in UPDRS Part 2 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
Mean Change in UPDRS Part 2 Sum Score
Scores on a scaleSPM962Placebo
Week 2-0.6 ± 2.1-0.5 ± 1.3
Week 4-1.2 ± 2.7-1.0 ± 1.9
Week 6-1.6 ± 2.9-1.4 ± 2.1
Week 8-1.6 ± 3.3-1.3 ± 2.4
Week 10-1.7 ± 3.2-1.2 ± 2.7
Week 12-1.8 ± 3.2-1.1 ± 2.9
End of maintenance period-1.8 ± 3.3-1.1 ± 2.9
SecondaryEfficacy Rate in UPDRS Part 2 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

Time frame:
Baseline, every two weeks
Reported as:
Number · Percentage of participants
Efficacy Rate in UPDRS Part 2 Sum Score
Percentage of participantsSPM962Placebo
≥20% decrease (Week 2)36.4 (26.3 to 46.4)13.6 (6.5 to 20.8)
≥20% decrease (Week 4)46.6 (36.2 to 57.0)34.1 (24.2 to 44.0)
≥20% decrease (Week 6)52.3 (41.8 to 62.7)40.9 (30.6 to 51.2)
≥20% decrease (Week 8)56.8 (46.5 to 67.2)43.2 (32.8 to 53.5)
≥20% decrease (Week 10)58.0 (47.6 to 68.3)38.6 (28.5 to 48.8)
≥20% decrease (Week 12)61.4 (51.2 to 71.5)39.8 (29.5 to 50.0)
≥20% decrease (End of maintenance period)60.2 (50.0 to 70.5)39.8 (29.5 to 50.0)
≥30% decrease (Week 2)20.5 (12.0 to 28.9)13.6 (6.5 to 20.8)
≥30% decrease (Week 4)36.4 (26.3 to 46.4)19.3 (11.1 to 27.6)
≥30% decrease (Week 6)43.2 (32.8 to 53.5)28.4 (19.0 to 37.8)
≥30% decrease (Week 8)43.2 (32.8 to 53.5)25.0 (16.0 to 34.0)
≥30% decrease (Week 10)43.2 (32.8 to 53.5)29.5 (20.0 to 39.1)
≥30% decrease (Week 12)48.9 (38.4 to 59.3)26.1 (17.0 to 35.3)
≥30% decrease (End of maintenance period)48.9 (38.4 to 59.3)26.1 (17.0 to 35.3)
SecondaryUPDRS Part 3 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
UPDRS Part 3 Sum Score
Scores on a scaleSPM962Placebo
Week 2-2.6 ± 4.2-1.7 ± 3.9
Week 4-4.3 ± 5.2-2.7 ± 4.7
Week 6-5.7 ± 6.3-3.3 ± 5.3
Week 8-6.1 ± 6.7-3.3 ± 5.8
Week 10-6.4 ± 6.7-3.4 ± 5.8
Week 12-6.6 ± 7.2-3.1 ± 6.2
End of maintenance period-6.6 ± 7.2-3.0 ± 6.2
SecondaryEfficacy Rate in UPDRS Part 3 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

Time frame:
Baseline, every two weeks
Reported as:
Number · Percentage of participants
Efficacy Rate in UPDRS Part 3 Sum Score
Percentage of participantsSPM962Placebo
≥20% decrease (Week 2)35.2 (25.2 to 45.2)19.3 (11.1 to 27.6)
≥20% decrease (Week 4)52.3 (41.8 to 62.7)28.4 (19.0 to 37.8)
≥20% decrease (Week 6)62.5 (52.4 to 72.6)35.2 (25.2 to 45.2)
≥20% decrease (Week 8)67.0 (57.2 to 76.9)37.0 (27.4 to 47.6)
≥20% decrease (Week 10)70.5 (60.9 to 80.0)42.0 (31.7 to 52.4)
≥20% decrease (Week 12)70.5 (60.9 to 80.0)40.9 (30.6 to 51.2)
≥20% decrease (End of maintenance period)70.5 (60.9 to 80.0)40.9 (30.6 to 51.2)
≥30% decrease (Week 2)22.7 (14.0 to 31.5)15.9 (8.3 to 23.6)
≥30% decrease (Week 4)36.4 (26.3 to 46.4)21.6 (13.0 to 30.2)
≥30% decrease (Week 6)52.3 (41.8 to 62.7)23.9 (15.0 to 32.8)
≥30% decrease (Week 8)54.5 (44.1 to 64.9)28.4 (19.0 to 37.8)
≥30% decrease (Week 10)58.0 (47.6 to 68.3)29.5 (20.0 to 39.1)
≥30% decrease (Week 12)60.2 (50.0 to 70.5)28.4 (19.0 to 37.8)
≥30% decrease (End of maintenance period)60.2 (50.0 to 70.5)28.4 (19.0 to 37.8)
SecondaryUPDRS Part 1 Sum Score

MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
UPDRS Part 1 Sum Score
Scores on a scaleSPM962Placebo
Week 2-0.17 ± 0.46-0.01 ± 0.28
Week 4-0.17 ± 0.75-0.11 ± 0.49
Week 6-0.14 ± 0.89-0.13 ± 0.58
Week 8-0.23 ± 0.89-0.07 ± 0.56
Week 10-0.25 ± 0.91-0.11 ± 0.63
Week 12-0.25 ± 0.91-0.05 ± 0.88
End of maintenance period-0.25 ± 0.91-0.05 ± 0.88
SecondaryUPDRS Part 4 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
UPDRS Part 4 Sum Score
Scores on a scaleSPM962Placebo
Week 20.19 ± 0.450.09 ± 0.33
Week 40.28 ± 0.790.08 ± 0.38
Week 60.18 ± 0.540.03 ± 0.39
Week 80.20 ± 0.610.09 ± 0.42
Week 100.19 ± 0.620.03 ± 0.44
Week 120.18 ± 0.640.05 ± 0.48
End of maintenance period0.18 ± 0.640.03 ± 0.47
SecondaryTotal of Each Sum Score of UPDRS Part 1, 2, 3, and 4

Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, every two weeks
Reported as:
Mean · Scores on a scale
Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4
Scores on a scaleSPM962Placebo
Week 2-3.3 ± 5.9-2.1 ± 4.6
Week 4-5.4 ± 7.1-3.8 ± 5.8
Week 6-7.2 ± 8.7-4.7 ± 6.7
Week 8-7.7 ± 9.4-4.6 ± 7.6
Week 10-8.1 ± 9.6-4.7 ± 7.7
Week 12-8.5 ± 9.9-4.1 ± 8.5
End of maintenance period-8.5 ± 9.9-4.1 ± 8.5
SecondaryThe Modified Hoehn and Yahr Stage

Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.

Time frame:
Baseline, end of maintenance period
Reported as:
Number · Percentage of participants
The Modified Hoehn and Yahr Stage
Percentage of participantsSPM962Placebo
Increased8.19.1
Not changed66.371.6
Decreased25.619.3

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM962—2/90 (2.2%)73/90 (81.1%)
Placebo—0/90 (0%)55/90 (61.1%)
Most frequent serious events
Most frequent serious events
EventSPM962Placebo
Cerebral InfarctionVascular disorders1/900/90
MyelopathyNervous system disorders1/900/90
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSPM962Placebo
Application Site ReactionGeneral disorders42/9020/90
NauseaGastrointestinal disorders21/905/90
NasopharyngitisInfections and infestations11/9015/90
VomitingGastrointestinal disorders14/901/90
SomnolencePsychiatric disorders13/904/90
ConstipationGastrointestinal disorders12/905/90
ContusionInjury, poisoning and procedural complications1/907/90
InsomniaPsychiatric disorders6/902/90
RashSkin and subcutaneous tissue disorders0/906/90
Blood Creatine Phosphokinase IncreasedInvestigations4/902/90

Baseline characteristics

Excluded 3 subjects (SPM962:2, placebo:1) because lack of assessment of efficacy, and 1 (plasebo) for not matching with the inclusion criteria.

Age, Categorical
Age, Categorical(Participants)SPM962PlaceboTotal
<=18 years000
Between 18 and 65 years363571
>=65 years5253105
Age, Continuous
Age, Continuous(years)SPM962PlaceboTotal
Mean65.1 ± 8.166.2 ± 7.965.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)SPM962PlaceboTotal
Female5551106
Male333770
Region of Enrollment
Region of Enrollment(participants)SPM962PlaceboTotal
Japan8888176
08

Study locations

6 sites
  • Chubu region, Japan
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyushu region, Japan
  • Tohoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Oct 1, 2007
Start
Sep 2007
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Mar 19, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00537485
Responsible party
Sponsor
First posted
Oct 1, 2007
Start date
Sep 2007
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Mar 19, 2014
Last update
Mar 19, 2014

Study contacts

Katsuhisa Saito
study director · New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion